| pubmed-article:16504154 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0337810 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0278882 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0340305 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0021735 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0677850 | lld:lifeskim |
| pubmed-article:16504154 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:16504154 | pubmed:dateCreated | 2006-4-3 | lld:pubmed |
| pubmed-article:16504154 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:abstractText | High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile. The safety analysis in the first 169 patients who completed the treatment is here described. | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16504154 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16504154 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16504154 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16504154 | pubmed:issn | 1471-2407 | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:RidolfiRugger... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:Chiarion-Sile... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:GuidaMicheleM | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:RomaniniAnton... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:PaccagnellaAd... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:NaglieriEmanu... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:SilvestriBarb... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:MichiaraMaria... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:Del... | lld:pubmed |
| pubmed-article:16504154 | pubmed:author | pubmed-author:Dalla... | lld:pubmed |
| pubmed-article:16504154 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:16504154 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:16504154 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16504154 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16504154 | pubmed:pagination | 44 | lld:pubmed |
| pubmed-article:16504154 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:meshHeading | pubmed-meshheading:16504154... | lld:pubmed |
| pubmed-article:16504154 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16504154 | pubmed:articleTitle | Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]. | lld:pubmed |
| pubmed-article:16504154 | pubmed:affiliation | Department of Medical Oncology, University Hospital, Padua, Italy. mgaliz@tiscali.it | lld:pubmed |
| pubmed-article:16504154 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16504154 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:16504154 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:16504154 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16504154 | lld:pubmed |
